FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/24/2026
Back to search
Official data from USPTO
THERAVECTYS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
THERAVECTYS
ST13
US500000079427841Class
1, 5, 40, 42, 44
Filing
79427841
Registration
8182382
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
23
Latest update
06/24/2026
Trademark type
Word
Nice classes
1, 5, 40, 42, 44
Filing date
05/15/2025
Registration date
03/24/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/24/2026
Last transaction
06/24/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
FR
Examiner
DAVIS, MARC STEPHEN
Law office
N40
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
THERAVECTYS
Representatives
Joseph Sofer Ipsilon USA, LLP
Technical classification
Nice Classes
Class 1Class 5Class 40Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical preparations for use in industry and science; chemical preparations for scientific useother than for medical or veterinary use; biological preparations for use in industry and science; chemical reagents other than for medical or veterinary use; chemical preparations for analyses in laboratories other than for medical or veterinary use; diagnostic preparations other than for medical or veterinary use; lentiviral vectors for scientific research.
Class 5
Pharmaceutical and veterinary preparations for the treatment of cancerinfectious diseases and emerging infectious diseases; vaccines; pharmaceutical preparations containing lentiviral vectors for medicalpharmaceutical and veterinary useparticularly for the treatment of cancerinfectious diseases and emerging infectious diseases; chemicalbiological and pharmaceutical preparations for therapeuticmedicalpharmaceutical and veterinary useparticularly for the treatment of cancerinfectious diseases and emerging infectious diseases; diagnostic preparations for therapeuticmedical and veterinary use; chemical reagents for medical or veterinary use.
Class 40
Pharmaceutical product custom manufacturing to order for third parties; vaccine manufacturing services to order for third parties.
Class 42
Scientific research for medical purposes; research and development services for pharmaceutical preparations; conducting clinical trials in the nature of scientific research; clinical research for scientific purposes; conducting scientific feasibility studies and analyses; biologicalbiotechnologicalbiochemicalmedical and pharmaceutical research and development services for third parties; evaluation of the efficacy of pharmaceutical products.
Class 44
Medical analysis and medical diagnosis services for the treatment of cancerinfectious diseases and emerging infectious diseases; medical analyses of blood samples; medical assistance services relating to medicine and health care; provision of medical information.
Publications
History of USPTO decisions and trademark events.
23 publications found
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/24/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
03/24/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/03/2026
PUBO
PUBLISHED FOR OPPOSITION
02/03/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/28/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/08/2026
XAEC
EXAMINER'S AMENDMENT ENTERED
01/08/2026
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/08/2026
GNEA
EXAMINERS AMENDMENT E-MAILED
01/08/2026
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/08/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/06/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/06/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/06/2026
RFNT
REFUSAL PROCESSED BY IB
12/11/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/26/2025
RFRR
REFUSAL PROCESSED BY MPU
11/26/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
10/10/2025
CNRT
NON-FINAL ACTION WRITTEN
10/09/2025
DOCK
ASSIGNED TO EXAMINER
09/28/2025
MAFR
APPLICATION FILING RECEIPT MAILED
07/18/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/18/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/17/2025
Continuous trademark protection
Get notified about every new filing that threatens THERAVECTYS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.